Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezo-ADT Trial: Fezolinetant for Vasomotor Symptoms in Men With Prostate Cancer
NCT06957691Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in vasomotor symptoms comparing Fezolinetant with Placebo (2 arms). Primary endpoints: Change in the Frequency of Vasomotor Symptoms at 4 weeks and Hepatic safety assessed by liver function tests at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06957691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957691.